跳至主要内容
临床试验/NCT02458313
NCT02458313已完成1 期

Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults

University of Colorado, Denver1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2016年4月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
61
试验地点
1
主要终点
Neuronal Response to Visual Food Cues

研究概览

简要总结

Obesity is a serious and growing health problem in the United States. Obesity is associated with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased quality of life and increased mortality. Given the health and quality-of-life effects of obesity, developing effective treatments clearly is an important goal.

This study plans to learn more about the effects of an investigational new drug (DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to affect appetite, the investigators are interested in studying effects of the study drug, which has some similarities to nicotine, on how your brain responds to such things as pictures of food. The study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Overweight/obese (BMI > 27)
  • Between 21-65 years old

排除标准

  • Known cardiovascular disease (e.g., coronary artery disease, uncontrolled hypertension
  • Women capable of conception (must be post-menopausal, surgically sterilized, or have adhered to an anti-contraception birth control regimen for at least 1 year)
  • Nicotine use
  • Significant endocrine/metabolic disease
  • Kidney disease
  • Neurological illness
  • Liver disease
  • Medication use affecting appetite and/or metabolism
  • MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)

研究组 & 干预措施

DMXB-A

Experimental

150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.

干预措施: DMXB-A (Drug)

Placebo

Placebo Comparator

Placebo capsules b.i.d. for 12 weeks.

干预措施: Placebo (Other)

结局指标

主要结局

Neuronal Response to Visual Food Cues

时间窗: 14 weeks

Neuronal response (insula) while viewing visual food cues

Resting-state Neuronal Response

时间窗: 14 weeks

Neuronal response (default mode network) during rest

次要结局

  • Body Weight(14 weeks)
  • Fat Mass(14 weeks)
  • Appetite Rating(14 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验